Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00144859 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: SB681323

Sponsor

GlaxoSmithKline